(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on developing therapies for serious rare and ultra-rare genetic diseases, on Tuesday reported a narrower loss for the third quarter of 2026, driven by higher revenues and lower research and dev
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.